Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinisches Magazin 2/2018

27.02.2018 | Intensivmedizin

Krebspatienten in der operativen Intensivmedizin

verfasst von: DESA Univ.-Prof. Dr. Thorsten Annecke, Dr. Andreas Hohn, Priv.-Doz. Dr. Boris Böll, Priv.-Doz. Dr. Matthias Kochanek

Erschienen in: Wiener klinisches Magazin | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Die Prävalenz onkologischer Erkrankungen ist in den vergangenen Jahrzehnten stetig angestiegen. Durch neue Therapieoptionen können immer mehr Patienten mit einem kurativen Therapieansatz behandelt werden. Diese individualisierten und teilweise sehr aggressiven Therapien können jedoch auch zu schweren Nebenwirkungen führen. Diese sollten als wichtige Differenzialdiagnosen zu anderen vitalbedrohlichen Krankheitsbildern auch dem im OP und als Intensivmediziner tätigen Anästhesisten bekannt sein. Krebspatienten werden häufig auf operativen Intensivstationen aufgenommen, um Komplikationen der malignen Grunderkrankung oder auch Nebenwirkungen einer operativen oder konservativen Therapie zu behandeln. Aktuelle Untersuchungen zeigen, dass die maligne Grunderkrankung entgegen bisheriger Annahme keinen wesentlichen Einfluss auf das Intensivüberleben hat. Bei der Aufnahme eines onkologischen Patienten sollte daher die akut vorliegende Organdysfunktion zunächst im Vordergrund stehen. Bei der Therapiezielplanung gilt es, nicht zu übersehen, wann ein kuratives in ein palliatives Konzept übergehen muss. Hierfür müssen neue Aufnahmestrategien und -kriterien entwickelt und evaluiert werden. In diesem Übersichtsartikel werden Diagnosen und Therapien häufiger intensivmedizinischer Krankheitsbilder von onkologischen Patienten sowie Nebenwirkungen moderner onkologischer Therapien dargelegt und Aufnahmestrategien für Patienten mit malignen Erkrankungen vorgestellt.
Literatur
1.
3.
Zurück zum Zitat Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E et al (2010) Cancer and inflammation: promise for biologic therapy. J Immunother 33(4):335–351 CrossRefPubMedPubMedCentral Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E et al (2010) Cancer and inflammation: promise for biologic therapy. J Immunother 33(4):335–351 CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Huitink JM, Teoh WH (2013) Current cancer therapies – a guide for perioperative physicians. Best Pract Res Clin Anaesthesiol 27(4):481–492 CrossRefPubMed Huitink JM, Teoh WH (2013) Current cancer therapies – a guide for perioperative physicians. Best Pract Res Clin Anaesthesiol 27(4):481–492 CrossRefPubMed
5.
Zurück zum Zitat Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6):417–427 CrossRefPubMed Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6):417–427 CrossRefPubMed
6.
Zurück zum Zitat Mahoney KM, Rennert PD, Freeman GJ (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14(8):561–584 CrossRefPubMed Mahoney KM, Rennert PD, Freeman GJ (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14(8):561–584 CrossRefPubMed
8.
Zurück zum Zitat Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent JL (2009) Characteristics and outcomes of cancer patients in European ICUs. Crit Care 13(1):R15 CrossRefPubMedPubMedCentral Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent JL (2009) Characteristics and outcomes of cancer patients in European ICUs. Crit Care 13(1):R15 CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Lambertz R, Drinhaus H, Schedler D, Bludau M, Schroder W, Annecke T (2016) Perioperative management of transthoracic oesophagectomies: fundamentals of interdisciplinary care and new approaches to accelerated recovery after surgery. Anaesthesist 65(6):458–466 CrossRefPubMed Lambertz R, Drinhaus H, Schedler D, Bludau M, Schroder W, Annecke T (2016) Perioperative management of transthoracic oesophagectomies: fundamentals of interdisciplinary care and new approaches to accelerated recovery after surgery. Anaesthesist 65(6):458–466 CrossRefPubMed
10.
Zurück zum Zitat Beutel G, Schellongowski P, Kiehl M, Kochanek M (2017) Intensive care of hematological and oncological patients: recent challenges. Dtsch Med Wochenschr 142(7):500–505 CrossRefPubMed Beutel G, Schellongowski P, Kiehl M, Kochanek M (2017) Intensive care of hematological and oncological patients: recent challenges. Dtsch Med Wochenschr 142(7):500–505 CrossRefPubMed
11.
Zurück zum Zitat von Bergwelt-Baildon M, Boll B, Shimabukuro-Vornhagen A, Kochanek M (2013) Hematologic and oncologic emergencies. Med Klin Intensivmed Notfmed 108(3):184–190 CrossRef von Bergwelt-Baildon M, Boll B, Shimabukuro-Vornhagen A, Kochanek M (2013) Hematologic and oncologic emergencies. Med Klin Intensivmed Notfmed 108(3):184–190 CrossRef
13.
Zurück zum Zitat Azoulay E, Lemiale V, Mokart D, Pene F, Kouatchet A, Perez P, Vincent F, Mayaux J, Benoit D, Bruneel F et al (2014) Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med 40(8):1106–1114 CrossRefPubMed Azoulay E, Lemiale V, Mokart D, Pene F, Kouatchet A, Perez P, Vincent F, Mayaux J, Benoit D, Bruneel F et al (2014) Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med 40(8):1106–1114 CrossRefPubMed
14.
Zurück zum Zitat Maschmeyer G, Carratala J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M et al (2015) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 26(1):21–33 CrossRefPubMed Maschmeyer G, Carratala J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M et al (2015) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 26(1):21–33 CrossRefPubMed
15.
Zurück zum Zitat Rieger C, Barlow S, Maschmeyer G (2014) What’s new in diagnosis and antimicrobial therapy of febrile neutropenic patients with lung infiltrates? Intensive Care Med 40(10):1549–1552 CrossRefPubMed Rieger C, Barlow S, Maschmeyer G (2014) What’s new in diagnosis and antimicrobial therapy of febrile neutropenic patients with lung infiltrates? Intensive Care Med 40(10):1549–1552 CrossRefPubMed
16.
Zurück zum Zitat Soares M, Salluh JI, Azoulay E (2010) Noninvasive ventilation in patients with malignancies and hypoxemic acute respiratory failure: a still pending question. J Crit Care 25(1):37–38 CrossRefPubMed Soares M, Salluh JI, Azoulay E (2010) Noninvasive ventilation in patients with malignancies and hypoxemic acute respiratory failure: a still pending question. J Crit Care 25(1):37–38 CrossRefPubMed
17.
Zurück zum Zitat Knight T, Ahn S, Rice TW, Cooksley T (2017) Acute oncology care: a narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors. Eur J Intern Med 45:59–65 CrossRefPubMed Knight T, Ahn S, Rice TW, Cooksley T (2017) Acute oncology care: a narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors. Eur J Intern Med 45:59–65 CrossRefPubMed
18.
Zurück zum Zitat Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C (2003) Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol 82(2):98–103 CrossRefPubMed Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C (2003) Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol 82(2):98–103 CrossRefPubMed
19.
Zurück zum Zitat Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36(5):396–407 CrossRefPubMed Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36(5):396–407 CrossRefPubMed
20.
Zurück zum Zitat Christofilopoulou S, Charvalos E, Petrikkos G (2002) Could procalcitonin be a predictive biological marker in systemic fungal infections?. Study of 14 cases. Eur J Intern Med 13(8):493–495 CrossRefPubMed Christofilopoulou S, Charvalos E, Petrikkos G (2002) Could procalcitonin be a predictive biological marker in systemic fungal infections?. Study of 14 cases. Eur J Intern Med 13(8):493–495 CrossRefPubMed
21.
Zurück zum Zitat Buhaescu I, Yood RA, Izzedine H (2010) Serum procalcitonin in systemic autoimmune diseases – where are we now? Semin Arthritis Rheum 40(2):176–183 CrossRefPubMed Buhaescu I, Yood RA, Izzedine H (2010) Serum procalcitonin in systemic autoimmune diseases – where are we now? Semin Arthritis Rheum 40(2):176–183 CrossRefPubMed
22.
Zurück zum Zitat Bihan H, Becker KL, Snider RH, Nylen E, Vittaz L, Lauret C, Modigliani E, Moretti JL, Cohen R (2003) Calcitonin precursor levels in human medullary thyroid carcinoma. Thyroid 13(8):819–822 CrossRefPubMed Bihan H, Becker KL, Snider RH, Nylen E, Vittaz L, Lauret C, Modigliani E, Moretti JL, Cohen R (2003) Calcitonin precursor levels in human medullary thyroid carcinoma. Thyroid 13(8):819–822 CrossRefPubMed
24.
Zurück zum Zitat Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45(3):486–552 CrossRefPubMed Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45(3):486–552 CrossRefPubMed
26.
Zurück zum Zitat Inauen R, Cathomas R, Boehm T, Koeberle D, Pestalozzi BC, Gillessen S, von Moos R (2007) Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. Oncology 72(3):209–210 CrossRefPubMed Inauen R, Cathomas R, Boehm T, Koeberle D, Pestalozzi BC, Gillessen S, von Moos R (2007) Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. Oncology 72(3):209–210 CrossRefPubMed
27.
Zurück zum Zitat Kroschinsky F, Stolzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P, Intensive Care H, Oncological Patients Collaborative G (2017) New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care 21(1):89 CrossRefPubMedPubMedCentral Kroschinsky F, Stolzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P, Intensive Care H, Oncological Patients Collaborative G (2017) New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care 21(1):89 CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51–60 CrossRefPubMed Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51–60 CrossRefPubMed
30.
Zurück zum Zitat Ranpura V, Hapani S, Chuang J, Wu S (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 49(3):287–297 CrossRefPubMed Ranpura V, Hapani S, Chuang J, Wu S (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 49(3):287–297 CrossRefPubMed
31.
Zurück zum Zitat Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305(5):487–494 CrossRefPubMed Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305(5):487–494 CrossRefPubMed
32.
Zurück zum Zitat Azoulay E, Pene F, Darmon M, Lengline E, Benoit D, Soares M, Vincent F, Bruneel F, Perez P, Lemiale V et al (2015) Managing critically ill hematology patients: time to think differently. Blood Rev 29(6):359–367 CrossRefPubMed Azoulay E, Pene F, Darmon M, Lengline E, Benoit D, Soares M, Vincent F, Bruneel F, Perez P, Lemiale V et al (2015) Managing critically ill hematology patients: time to think differently. Blood Rev 29(6):359–367 CrossRefPubMed
33.
Zurück zum Zitat Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J, Vincent F, Nyunga M, Bruneel F, Laisne LM et al (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium – a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol 31(22):2810–2818 CrossRefPubMed Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J, Vincent F, Nyunga M, Bruneel F, Laisne LM et al (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium – a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol 31(22):2810–2818 CrossRefPubMed
34.
Zurück zum Zitat Puxty K, McLoone P, Quasim T, Kinsella J, Morrison D (2014) Survival in solid cancer patients following intensive care unit admission. Intensive Care Med 40(10):1409–1428 CrossRefPubMed Puxty K, McLoone P, Quasim T, Kinsella J, Morrison D (2014) Survival in solid cancer patients following intensive care unit admission. Intensive Care Med 40(10):1409–1428 CrossRefPubMed
35.
Zurück zum Zitat Azoulay E, Soares M, Darmon M, Benoit D, Pastores S, Afessa B (2011) Intensive care of the cancer patient: recent achievements and remaining challenges. Ann Intensive Care 1(1):5 CrossRefPubMedPubMedCentral Azoulay E, Soares M, Darmon M, Benoit D, Pastores S, Afessa B (2011) Intensive care of the cancer patient: recent achievements and remaining challenges. Ann Intensive Care 1(1):5 CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Ney L, Annecke T (2014) Intercultural differences in the treatment of severely injured patients with poor prognosis. Unfallchirurg 117(2):167–168 CrossRefPubMed Ney L, Annecke T (2014) Intercultural differences in the treatment of severely injured patients with poor prognosis. Unfallchirurg 117(2):167–168 CrossRefPubMed
37.
Zurück zum Zitat Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474 CrossRefPubMed Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474 CrossRefPubMed
38.
Zurück zum Zitat Schellongowski P (2013) Der hämatologisch-onkologische Patienet auf der Intensivstation. Med Klin Intensivmed Notfmed 108:203–208 CrossRefPubMed Schellongowski P (2013) Der hämatologisch-onkologische Patienet auf der Intensivstation. Med Klin Intensivmed Notfmed 108:203–208 CrossRefPubMed
39.
Zurück zum Zitat Lecuyer L, Chevret S, Thiery G, Darmon M, Schlemmer B, Azoulay E (2007) The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation. Crit Care Med 35(3):808–814 CrossRefPubMed Lecuyer L, Chevret S, Thiery G, Darmon M, Schlemmer B, Azoulay E (2007) The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation. Crit Care Med 35(3):808–814 CrossRefPubMed
40.
Zurück zum Zitat Schuster DP, Marion JM (1983) Precedents for meaningfulrecovery during treatment in a medical intensive care unit. Outcome in patients with hematologic malignancy. Am J Med 75(3):402–408 CrossRefPubMed Schuster DP, Marion JM (1983) Precedents for meaningfulrecovery during treatment in a medical intensive care unit. Outcome in patients with hematologic malignancy. Am J Med 75(3):402–408 CrossRefPubMed
41.
Zurück zum Zitat Estopa R, Torres Marti A, Kastanos N, Rives A, Agusti-Vidal A, Rozman C (1984) Acute respiratory failure in severe hematologic disorders. Crit Care Med 12(1):26–28 CrossRefPubMed Estopa R, Torres Marti A, Kastanos N, Rives A, Agusti-Vidal A, Rozman C (1984) Acute respiratory failure in severe hematologic disorders. Crit Care Med 12(1):26–28 CrossRefPubMed
42.
Zurück zum Zitat Peters SG, Meadows JA 3rd, Gracey DR (1988) Outcome of respiratory failure in hematologic malignancy. Chest (94)(1):99-102 CrossRefPubMed Peters SG, Meadows JA 3rd, Gracey DR (1988) Outcome of respiratory failure in hematologic malignancy. Chest (94)(1):99-102 CrossRefPubMed
43.
Zurück zum Zitat Groeger JS, White P Jr, Nierman DM, Glassman J, Shi W, Horak D, Proce K (1999) Outcome for cancer patients requiring mechanical ventilation. J Clin Oncol 17(3):991–997 CrossRefPubMed Groeger JS, White P Jr, Nierman DM, Glassman J, Shi W, Horak D, Proce K (1999) Outcome for cancer patients requiring mechanical ventilation. J Clin Oncol 17(3):991–997 CrossRefPubMed
44.
Zurück zum Zitat Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA, Colardyn FA (2003) Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complikation. Crit Care Med 31(1):104–112 CrossRefPubMed Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA, Colardyn FA (2003) Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complikation. Crit Care Med 31(1):104–112 CrossRefPubMed
45.
Zurück zum Zitat Depuydt PO, Benoit DD, Vandewounde KH, Decruyenaere JM, Colardyn FA (2004) Outcome in noninvasively and invasely ventilated hematologic patients with acute respiratory failure. Chest 126(4):1299–1306 CrossRefPubMed Depuydt PO, Benoit DD, Vandewounde KH, Decruyenaere JM, Colardyn FA (2004) Outcome in noninvasively and invasely ventilated hematologic patients with acute respiratory failure. Chest 126(4):1299–1306 CrossRefPubMed
46.
Zurück zum Zitat Soares M, Salluh JIF, Torres VBL, Leal JVR, Spector N (2008) Short- and long -term outcomes of critically ill paients with cancer and prolonged ICU lengh of stay. Chest 134(3):520–526 CrossRefPubMed Soares M, Salluh JIF, Torres VBL, Leal JVR, Spector N (2008) Short- and long -term outcomes of critically ill paients with cancer and prolonged ICU lengh of stay. Chest 134(3):520–526 CrossRefPubMed
47.
Zurück zum Zitat Lecuyer L, Chevret S, Guidet B, Aegerter P, Martel P, Schlemmer B, Azoulay E (2008) Case volume and mortality in haematological patients with acute respiratory failure. Eur Respir J 32(3):748–754. CrossRefPubMed Lecuyer L, Chevret S, Guidet B, Aegerter P, Martel P, Schlemmer B, Azoulay E (2008) Case volume and mortality in haematological patients with acute respiratory failure. Eur Respir J 32(3):748–754. CrossRefPubMed
48.
Zurück zum Zitat Gristina GR, Antonelli M, Conti G, Ciarlone A, Rogante S, Rossi C, Bertolini G, GiViTi (Italian Group for the Evaluation of Interventions in Intensive Care Medicine) (2011) Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: a 5-year multicenter observation survey. Crit Care Med 39(10):2232–2239 CrossRefPubMed Gristina GR, Antonelli M, Conti G, Ciarlone A, Rogante S, Rossi C, Bertolini G, GiViTi (Italian Group for the Evaluation of Interventions in Intensive Care Medicine) (2011) Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: a 5-year multicenter observation survey. Crit Care Med 39(10):2232–2239 CrossRefPubMed
Metadaten
Titel
Krebspatienten in der operativen Intensivmedizin
verfasst von
DESA Univ.-Prof. Dr. Thorsten Annecke
Dr. Andreas Hohn
Priv.-Doz. Dr. Boris Böll
Priv.-Doz. Dr. Matthias Kochanek
Publikationsdatum
27.02.2018
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin / Ausgabe 2/2018
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-018-0218-1